![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Medtronic Wins Expanded Indication Trial for CoreValve System
Medtronic Wins Expanded Indication Trial for CoreValve System
![](https://www.fdanews.com/ext/resources/test/Device_Images2/Medtronic_Logo.gif?t=1433877334&width=430)
Medtronic received good news from the FDA, which has approved an expanded indication trial for CoreValve Evolut R system aortic stenosis patients who are at a low surgical mortality risk.
The IDE trial is scheduled to begin this spring and is expected to include 1,200 patients with severe aortic stenosis who have less than a 3 percent risk of mortality.
Also available in Europe, the CoreValve Evolut R transcatheter valve and accompanying CoreValve EnVeo R delivery catheter system gained FDA approval last June. — Anisa Jibrell
Upcoming Events
-
21Oct